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ABSTRACT
Objectives: Cardiac resynchronisation therapy (CRT)
improves morbidity and mortality in heart failure (HF).
Impaired endothelial function, as measured by flow-
mediated dilation (FMD) is associated with increased
morbidity and mortality in HF and may help to
differentiate responders from non-responders.
Methods: 19 patients were recruited, comprising 94%
men, mean age 69±8 years, New York Heart
Association functional classes II–IV, QRSd 161±21 ms
and mean left ventricular ejection fraction 26±8%.
Markers of response and FMD were measured at
baseline, 6 and 12 months following CRT.
Results: 14 patients were responders to CRT.
Responders had significant improvements in VO2
(12.6±1.7 to 14.7±1.5 mL/kg/min, p<0.05), quality of
life score (44.4±22.9–24.1±21.3, p<0.01), left
ventricular end diastolic volume (201.5±72.5 mL–121.3
±72.0 mL, p<0.01) and 6-min walk distance (374.0
±112.8 m at baseline to 418.1±105.3 m, p<0.05).
Baseline FMD in responders was 2.9±1.9% and 7.4
±3.73% in non-responders (p<0.05).
Conclusions: Response to CRT at 6 and 12 months is
predicted by baseline FMD. This study confirms that
FMD identifies responders to CRT, due to endothelium-
dependent mechanisms alone.
INTRODUCTION
In cardiovascular diseases, such as heart
failure (HF), impairment of peripheral vas-
cular endothelial function is common and
can differentiate patients in terms of aeti-
ology, functional class and prognosis.1–3 It
has been demonstrated that endothelial
function improves following successful use of
a treatment such as cardiac resynchronisation
therapy (CRT) and, more importantly, that a
speciﬁc measure of endothelial function,
termed ﬂow-mediated dilation (FMD), mea-
sured a priori, can assist in the selection of
patients likely to beneﬁt from CRT.4 5 This
ﬁnding is important, as while it is well known
that only two-thirds of patients implanted
with CRT derive clinical beneﬁt, current
guidelines for CRT implantation (NYHA
functional classes II–IV, EF%<35% and
QRSd>120 ms) do not adequately select
responders. Similarly, it is well known that
echocardiographic parameters of dyssyn-
chrony do not predict response.6
Akar ﬁrst demonstrated that those with
impaired endothelial function at baseline
were more likely to respond to CRT and an
improvement in endothelial function at
3 months follow-up post-CRT implantation.4
This study sought to conﬁrm these ﬁndings,
but with notable key differences. First, using
peak VO2, in addition to 6-min walk distance
(6MWD), as a marker of response; second,
using echocardiography-guided CRT opti-
misation protocol for all patients; third,
following-up patients at 6 and 12 months to
capture later responders; fourth, investigate
the role of non-endothelium-dependent
mechanisms, speciﬁcally nitroglycerine-
mediated dilation (NMD) and ﬁnally, pos-
sible confounding of patient variables, for
example, pacing site, scar location that may
also inﬂuence CRT response.
NMD is an endothelial independent
measure of vascular function, speciﬁcally, the
maximal dilatory response to an adminis-
tered nitric oxide (NO) donor, such as gly-
ceryl trinitrate (GTN), and changes in this
metric could confound the results of FMD,
KEY QUESTIONS
What is already known about this subject?
▸ Response to cardiac resynchronisation therapy
(CRT) is variable, and current guidelines do not
adequately identify responders.
What does this study add?
▸ This study demonstrates measures of endothe-
lial function, specifically flow-mediated dilation
(FMD), accurately predict response to CRT at 6
and 12 months.
How might this impact on clinical practice?
▸ FMD could be used to identify potential respon-
ders at baseline to CRT.
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which has not been investigated. The working hypothesis
was that there would be a signiﬁcant difference in four
measures of response at 6 and 12 months, and this
response could be predicted by measures of endothelial
dysfunction at baseline, prior to CRT implantation.
MATERIALS AND METHODS
Ethics
This study was approved by the local National Health
Service (NHS) health research authority (NRES number
10/H0802/71). The authors take full responsibility for
the integrity of the data. All authors have read and
agree to the manuscript as it is written. None had any
conﬂict of interest regarding this study. The patients
were screened for eligibility by a physician and a dedi-
cated clinical research fellow. All patients gave fully
informed written consent to take part in the project.
Inclusion criteria
All patients due to receive CRT based on current clinical
criteria at Shefﬁeld Teaching Hospitals NHS Trust were
considered for this study. That is, patients with an ejec-
tion fraction <35%, a QRSd>120 ms, NYHA functional
classes II–IV, and optimal medical therapy. A total of 21
patients were recruited at baseline, but two patients did
not complete follow-up, and therefore, are not included
in subsequent analysis.
Study design
Following patient recruitment, endothelial function was
assessed by means of FMD and NMD measured at base-
line and repeated at 12 months (±2 weeks) post-CRT
implantation. At 6 weeks post-CRT implantation, patients
were referred for routine echocardiography-guided CRT
optimisation, using the iterative method to optimise
atrioventricular delay and the aortic velocity time inte-
gral (VTI) method for the interventricular delay.
Assessment of endothelial function
Assessment of FMD was performed by a blinded investi-
gator in accordance with the 2011 guidelines.7 The
diameter of the brachial artery was measured (proximal
to the elbow) for 1 min, to obtain a baseline measure,
then a standard sphygmomanometer cuff was used over
the forearm and inﬂated to >30 mm Hg above systolic
blood pressure to occlude the forearm arteries.
Following cuff deﬂation the brachial artery diameter was
measured for a further 3 min. The artery was imaged
using a custom-built rig (ﬁgure 1), comprising a Vivid 7
ultrasound machine (GE Healthcare, New Jersey, USA),
and 2D Doppler probe with 8 MHz linear array. Images
were relayed to a laptop (ﬁgure 2) using Epiphan frame-
grabber device (Epiphan Systems Inc, Ottawa,
California, USA) and analysed off-line using Medical
imaging applications automated brachial analyser
(MIA-llc, Iowa, USA). FMD was calculated as the per-
centage change in diameter from baseline.
Following a period of 20 min rest after the FMD, the
same process was repeated but without the sphygman-
ometer in order to measure NMD. The patient was
given 800 µg of GTN sublingually, the brachial artery
imaged for a further 6 min, and the peak diameter
recorded. NMD was calculated as the percentage change
in diameter from baseline (ﬁgure 3).
Assessment of response to CRT
Investigators assessing the clinical response were blinded
to the FMD results and vice versa. A positive response to
CRT was deﬁned as that demonstrating an improvement
in all four areas, a >1 mL/kg/min increase in peak VO2,
a >10% reduction in left ventricular end-diastolic
volume (LVEDV), a >10% reduction in symptoms as
measured by the Minnesota living with heart failure
Figure 1 Custom built rig supporting the right upper arm and
forearm, enabling the arm to be splinted in the anatomical
position (elbow extended and forearm supinated), the
ultrasound (USS) probe positioned proximal to the elbow and
the sphygmomanometer cuff positioned distal to the elbow.
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questionnaire (MLWHFQ) and a >10% increase in
6MWD.
Peak VO2 was measured by a senior pulmonary physi-
ologist during a cardiopulmonary exercise test using a
ramp protocol on a static bicycle ergometer.
LVEDV was calculated by the modiﬁed Simpson’s rule
of stack discs using a 2D Vivid 7 echocardiography
machine (GE Healthcare, New Jersey, USA) to image the
apical two-chamber and four-chamber views. The images
were assessed by experienced research sonographers.
The MLWHFQ, a validated and well-tested quality of
life (QoL) questionnaire, speciﬁc for HF patients, and
assessing both the psychological and physiological
domains, was administered by the investigator.
The 6-min walk test measures the distance walked
unaided, at a normal pace on a ﬂat, hard, even surface
in 6 min, termed the 6MWD.
Statistics
Statistical analysis was performed using SPSS software
(V.21.0, SPSS Inc, Chicago, Illinois, USA). Assessment of
data for normality was carried out using Shapiro-Wilks
test. Parametric data are given in terms of the mean±SD.
Comparison of data within groups was performed using
a paired two-tailed Student’s t-test, and between groups
using a one way ANOVA with repeated measures.
Correlations were analysed with the Pearson’s product
coefﬁcient. Nominal data was analysed using a two-tailed
Fisher’s exact.
p Values of <0.05 were considered signiﬁcant. Simple
linear regression was used to study the association between
baseline FMD and baseline 6MWD, peak VO2, QRS dur-
ation, MLWHFQ and left ventricular (LV) volumes.
RESULTS
Baseline patient characteristics are summarised in table 1.
As can be seen, all patients had similar levels of LV impair-
ment and QRSd prolongation at baseline. There were no
signiﬁcant differences between the baseline measures of
response, such as LVEDV, peak VO2, MLWHFQ or 6WMD.
Response to CRT
According to the four independent criteria speciﬁed a
priori, a positive response to CRT was observed in 14 of
the 19 patients during follow-up (table 2 and ﬁgure 4).
Responders had signiﬁcant improvements in cardio-
respiratory ﬁtness, symptoms and cardiac function.
Speciﬁcally, at 12 months, responders had signiﬁcant
Figure 2 Screen shot of the MIA-IIc brachial analyser software recording the diameter of the brachial artery using B mode
ultrasound, by identification of the lines of Pignoli in real time (green box=region of interest, blue lines=endothelium tracker).
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improvements in VO2 (12.6±1.7 to 14.7±1.5 mL/kg/min,
p<0.05), QoL score (44.4±22.9 to 24.1±21.3, p<0.01),
LVEDV (201.5±72.5 to 121.3±72.0 mL, p<0.01) and 6MWD
(374.0±112.8 m at baseline to 418.1±105.3 m, p<0.05). The
non-responders failed to demonstrate a statistically signiﬁ-
cant improvement in any of these four criteria at 6 or
12 months.
There were no signiﬁcant differences during follow-up
in β-blocker or ACE-I/ARB dose, but there was, however,
a signiﬁcant reduction in loop diuretic requirement of
the responders at 12 months (83.1±24.9 to 62.2±37.6 mg,
p<0.05), whereas this increased, albeit non-signiﬁcantly
in non-responders (70.0±39.3 to 100.0±49.0 mg, p=0.12).
In terms of LV reverse remodelling, there was a signiﬁ-
cant reduction in left ventricular end systolic volume
(LVESV) in responders, at 12 months (156.5±57.3 to
127.0±39.4 mL, p<0.01), but this was not seen in non-
responders (116.4±68.2 to 109.6±77.8 mL, p=0.49).
Finally, there were no clinical events during the
12 months follow-up, such as hospitalisation or death.
Flow-mediated dilation
Baseline FMD in responders was 2.9±1.9% and 7.4±3.73%
in non-responders (p<0.05, ﬁgures 5A, C and 6A). There
was no difference in the resting diameter of the brachial
artery measured prior to cuff inﬂation between baseline,
6 and 12 months in all 19 patients (table 1) ruling out
the possibility that changes in the tone, or diameter, of
the resting brachial artery were responsible for the
changes in FMD. During follow-up, there was an improve-
ment in endothelial function as measured by FMD in the
responder group (ﬁgure 5A), and a deterioration in the
non-responder group (ﬁgure 5C), but these changes did
not reach statistical signiﬁcance.
Nitroglycerine-mediated dilation
There was no signiﬁcant difference in baseline NMD
between responders and non-responders (16.7±9.41%
and 21.0±10.1, respectively, p=0.41, ﬁgure 6B). During
follow-up, there was no signiﬁcant change in NMD, in
either the responders or non-responders (ﬁgure 5B, D).
FMD and response to CRT
There was no correlation between baseline FMD and
markers of response, nor any correlation between
improvement in FMD and improvement in markers of
response. Using logistic regression analysis, baseline
FMD independently predicts likelihood of response to
Figure 3 Demonstrating changes in brachial artery diameter, with FMD transient response following cuff deflation at 5 min
(frame ∼1800) and sustained NMD response following administration of sublingual GTN (frame ∼600), recording at a rate of 5
frames per second.
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CRT. This demonstrates that for every 1% reduction in
baseline FMD the likelihood of CRT increased by 8%
(ﬁgure 7).
Other factors affecting CRT response
As can be seen from table 3, regardless of response, the
majority of patients had an intraventricular conduction
delay of left bundle block morphology, pacing leads
placed in the right atrial appendage, right ventricular
apex and the lateral or posterior vein, and ﬁnally scar, if
present, in the anterior wall or septum. All 19 patients
were receiving over 95% biventricular pacing during
follow-up, veriﬁed with departmental pacing checks and
remote monitoring.
DISCUSSION
This study demonstrates that FMD predicts clinical
response to CRT, is lower at baseline in non-responders,
Table 1 Baseline characteristics of responders and non-responders
Responders (N=14) Non-responders (N=5) p Value
Demographics
Age (years) 68.7±9.1 71.8±4.2 0.53
Male 13 (93%) 5 (100%) 0.50
Ischaemic heart disease 8 (57%) 3 (60%) 0.52
Hypercholesterolaemia 10 (72%) 4 (80%) 0.49
Hypertension 7 (50%) 2 (40%) 0.53
Chronic kidney disease 4 (29%) 4 (80%) 0.20
Diabetes 5 (36%) 1 (20%) 0.49
ECG/echocardiography
QRSd (ms) 163.0±22.8 155.5±20.9 0.55
LVEDV (mL) 201.5±72.5 159.0±80.8 0.37
LVESV (mL) 156.5±57.3 116.4±68.2 0.23
SV (mL) 45.0±19.7 39.6±20.3 0.30
EF (%) 25.6±8.0 25.8±8.5 0.44
Medications (%)
ACE-I/ARB 13 (93) 5 (100) 0.24
β-Blocker 12 (86) 5 (100) 0.90
Loop diuretic 14 (100) 5 (100) 0.36
MRA 9 (64) 4 (80) 0.93
Brachial diameter (mm)
Baseline 4.43±0.67 4.40±0.63 0.94
6 months 4.47±0.54 4.50±0.37 0.94
12 months 4.56±0.57 4.71±0.36 0.56
ACE-I, ACE inhibitor; ARB, angiotensin receptor blocker; LVEDV, left ventricular end diastolic volume; LVESV, left ventricular end systolic
volume; MRA, mineralocorticoid receptor antagonist; QRSd, QRS duration; SV, stroke volume.
Table 2 Markers of response at baseline, 6 and 12 months
Markers of response Responders Non-responders p Value
Baseline
6MWD (m) 374.0±112.8 337.0±144.7 0.23
LVEDV (mL) 201.5±72.5 159.0±80.8 0.37
MLWHFQ 44.4±22.9 52.8±22.7 0.33
Peak VO2 (mL/kg/min) 12.5±1.6 13.9±2.7 0.25
6 months
6MWD (m) 391.0±108.1 337.0±144.7 N/A
LVEDV (mL) 157.0±77.3 172.4±126.2 N/A
MLWHFQ 24.4±19.1 37.0±20.6 N/A
Peak VO2 (mL/kg/min) 14.1±2.7 11.5±4.1 N/A
12 months
6MWD (m) 418.1±105.3 279.6±113.8 N/A
LVEDV (mL) 121.3±72.0 145.6±88.8 N/A
MLWHFQ 24.1±21.3 36.4±26.7 N/A
Peak VO2 (mL/kg/min) 14.7±1.5 12.8±3.9 N/A
6MWD, 6-minute walk distance; LVEDV, left ventricular end diastolic volume; MLWHFQ, =Minnesota living with heart failure questionnaire.
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but that FMD predicts response at 6 and 12 months. There
were no signiﬁcant clinical differences between the
responders and non-responders at baseline; all met the
current guidelines for CRT implantation. If FMD is used at
baseline to discriminate responders from non-responders,
then non-responders may not be exposed to potential
harms from a device they will ultimately not beneﬁt from.
It is uncertain why responders at baseline should have
lower FMD, as while patients with ischaemic cardiomyop-
athy often have worse endothelial function, it is patients
with non-ischaemic cardiomyopathy who typically dem-
onstrate a greater response to CRT.3 8 It is possible that
differences in endothelial function, are a result of
‘altered haemodynamics, peripheral shear stress, cardiac
loading conditions and neurohormonal activation’.4
Indeed, there was no signiﬁcant difference in HF aeti-
ology between the groups to otherwise account for this
difference in FMD at baseline. During follow-up, endo-
thelial function, as measured by FMD, appeared to
deteriorate in non-responders and improved in FMD in
responders, as found previously, although this was not
signiﬁcant in either case.4
There are a number of key procedural differences
between the author’s work and the previous studies,
including longer follow-up, markers of response, use of
optimisation, use of NMD and investigation of possible
confounding variables. The present study followed-up
patients for 12 months. This is consistent with large ran-
domised CRT trials, such as MUSTIC, MIRACLE and
CONTAK, and demonstrates that FMD predicts medium,
not just short-term response to CRT.9–11 As was previously
predicted, but not investigated, measures of response to
CRT based on brachial artery reactivity are entirely
endothelially mediated, with this study showing no signiﬁ-
cant differences in NMD before or after CRT.4 Unlike
previous work, there was no improvement in FMD follow-
ing CRT, indeed there was deterioration in both FMD
and NMD, suggesting a continuing decline in endothelial
function, but the study was not powered to detect these
changes. Cardiac function, cardiorespiratory ﬁtness and
symptoms were all measured at baseline and during
follow-up. Peak VO2 is considered the gold standard
measure of cardiorespiratory function, and is used in con-
junction with a signiﬁcant improvement in the other four
Figure 4 Response to cardiac resynchronisation therapy (CRT) (responders in white bars and non-responders in black bars).
(A) Changes in peak VO2. (B) Changes in the Minnesota Living with Heart Failure Questionnaire (MLWHFQ) score. (C) Changes
in Left Ventricular End Diastolic Volume (LVEDV) (D) Changes in 6-min walk distance (6MWD).
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Figure 5 Endothelial function at baseline and follow-up (responders in white bars and non-responders in black). (A) Changes in
flow-mediated dilation (FMD) following cardiac resynchronisation therapy (CRT) in responders, there were no significant
differences at 6 or 12 months. (B) Changes in nitroglycerine-mediated dilation (NMD) following CRT in responders, there were no
significant differences at 6 or 12 months. (C) Changes in flow-mediated dilation (FMD) following CRT in non-responders, there
were no significant differences at 6 or 12 months. (D) Changes in nitroglycerine-mediated dilation (NMD) following CRT in
non-responders, there were no significant differences at 6 or 12 months.
Figure 6 Box plots showing the
distribution of baseline brachial
artery flow-mediated dilation
(FMD) and
nitroglycerine-mediated dilation
(NMD). Responders to cardiac
resynchronisation therapy (CRT)
demonstrated impaired
endothelial function at baseline
that was significantly lower than
baseline in non-responders.
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markers of response, gave a more robust categorisation of
response, and reducing the element of chance, rather
than simply relying on one metric alone. As seen in table
3, there was also no signiﬁcant difference between other
possible extraneous factors inﬂuencing CRT response,
such as bundle branch morphology, presence of scar or
lead placement, for example, not investigated previously.
However, larger studies including scar location, lead
placement and type of device, will be required in order
to rule out such variables as inﬂuencing either CRT
response or indeed, FMD.
Endothelial dysfunction is important in cardiovascular
disease, and reﬂecting ‘increased arterial stiffness and
reduced compliance increase ventricular afterload and
left ventricular end-diastolic stress, and enhance dilation
and failure’, and ‘impaired function of the large epicar-
dial coronary arteries, as well as the coronary microcircu-
lation, which may cause or contribute to myocardial
ischemia’.2 Thus, FMD is not simply an arbitrary
number, but rather is a measure of the ﬁtness of the
patient’s endothelium, an important ‘organ’ which is
often overlooked. Indeed, exercise training can further
improve endothelial function following successful CRT
implantation and clinical response.12
Larger trials are needed to conﬁrm the power of FMD
to predict response to CRT before it can be used as part
of a randomised controlled trial and a threshold for
FMD predicting response is determined. Further work
will be needed in order to investigate the role of HF aeti-
ology in determining FMD and response to CRT, for
example, ischaemic versus non-ischaemic HF, the role of
comorbidity such as chronic kidney disease or pulmon-
ary hypertension, and also QRS morphology, for
example, left versus right bundle branch block.
This was a small prospective study, but it was
adequately powered to detect differences in baseline
FMD among the two groups.13 Limitations include a
slightly smaller response rate in the present study than
in larger randomised controlled trials. This can be
attributed to a small sample size and multimodal classiﬁ-
cation of response a priori. There was only one woman
and no ethnic minorities in this cohort, so it is difﬁcult
to translate the results to such populations. Deﬁning
response to CRT is problematic and subjective, for this
reason the authors decided that any responder must
demonstrate improvement in four different markers at
prespeciﬁed thresholds, for example, peak VO2, 6MWD,
LVEDV, MLWHFQ, widely used in the literature.14–20
This was to ensure, as much as possible, that any
response was true and not due to random variation, par-
ticularly in such a small patient population. While, the
non-responder group demonstrated an improvement in
Figure 7 Logistic regression analysis model of the
probability of response to cardiac resynchronisation therapy
(CRT) and baseline endothelial function using flow mediated
dilation (FMD). For every 1% reduction in baseline FMD, there
was an approximate 8% increase in the likelihood of CRT
response.
Table 3 Other factors affecting CRT response
Other factors Responders (%) Non-responders (%) p Value
Bundle branch block Left 13 (93) 5 (100) 0.56
CRT device P only 5 (36) 3 (60) 0.37
Right atrium
Lead position Appendage 9 (65) 4 (80) 0.65
Right ventricle
Apex 14 (100) 5 (100) 0.99
Left ventricle
Lateral vein 10 (72) 4 (80) N/A
Middle vein 1 (7) 0 (0)
Posterior vein 2 (14) 1 (20)
Epicardial 1 (7) 0 (0)
Presence of scar Anterior wall 4 (29) 2 (60) 0.91
Apex 1 (7) 0 (0)
Lateral wall 1 (7) 0 (0)
Inferior wall 1 (7) 0 (0)
Septum 1 (7) 1 (20)
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QoL, as measured by the MLWHFQ score, this was not
signiﬁcant and likely to be due to a combination of
chance and placebo effect.
CONCLUSIONS
In the current study, FMD predicts the response to CRT
at 6 and 12 months. These results conﬁrm previous work
reporting that measures of endothelial dysfunction iden-
tiﬁes response to CRT at 3 months, and by contrast,
NMD is not a predictor of response to, nor signiﬁcantly
inﬂuenced by, CRT. Consideration needs to be made to
using FMD in routine clinical practice in the selection of
patients for CRT. But ﬁrst, larger studies will be needed
to conﬁrm FMD’s predictive power, and determine why
patients with poorer endothelial function, at baseline,
are more likely to respond to CRT.
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